Developing breakthrough treatments through cutting-edge research and collaborative science
Learn MoreTransforming lives through innovative pharmaceutical research
Mcure Biosciences is a cutting-edge biotech startup based in Sunnyvale, CA dedicated to developing a novel pharmaceutical treatment to address unmet medical needs. Our team of world-class scientists and researchers work tirelessly to push the boundaries of what's possible
in modern medicine. Founded in 2022, we combine innovative research methodologies with state-of-the-art technology to accelerate drug discovery and development. Our approach integrates computational biology, molecular engineering, and clinical expertise to create transformative
therapies. We are committed to scientific excellence, patient-centered innovation, and collaborative partnerships that bring life-changing treatments to those who need them most.
Guided by purpose, driven by innovation
We pursue rigorous, evidence-based research that adheres to the highest scientific standards. Our commitment to excellence drives every aspect of our drug development process.
We embrace novel approaches and cutting-edge technologies to tackle the most challenging problems in pharmaceutical research and development.
Every decision we make is guided by our commitment to improving patient outcomes and addressing critical unmet medical needs in underserved communities.
World-class scientists and innovators dedicated to advancing human health
Founder and Chairman
short bio of qualifications
Chief Scientific Officer
M.D., Ph.D. from Harvard Medical School. Previously led research teams at leading biotech companies with multiple FDA approvals.
Chief Manufacturing Officer
Bio from kent
Scientific Director?
Neelima bio
science team/AI team
bios for whoever wants one
Our research contributions to the scientific community
This groundbreaking study demonstrates a new methodology for precision drug delivery that significantly reduces off-target effects while improving therapeutic efficacy in cancer treatment.
A comprehensive analysis of machine learning approaches to predict drug-protein binding affinities, accelerating the drug discovery timeline.
First-in-human trial results demonstrating excellent safety and tolerability of our lead compound in healthy volunteers.
Identification of novel molecular pathways implicated in neurodegeneration, opening new avenues for therapeutic intervention.